前收市價 | 0.8000 |
開市 | 2.6500 |
買盤 | 0.0000 |
賣出價 | 1.2500 |
拍板 | 115.00 |
到期日 | 2025-01-17 |
今日波幅 | 0.8000 - 2.6500 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 26 |
Apellis' (APLS) revenues rise on the back of the robust uptake of Syfovre for the GA indication. However, the recent regulatory setback in the EU for pegcetacoplan to treat GA is a woe.
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.